GlycoMark

06/28/2021

https://www.prnewswire.com/news-releases/new-late-breaking-data-at-the-american-diabetes-association-show-glycomark-may-be-an-effective-test-for-covid-19-severity-301320337.html?tc=eml_cleartime

/PRNewswire/ -- Precision Diabetes, Inc. and Patia announced today results from a study showing that the GlycoMark blood test may be an effective marker of...

04/15/2021

Precision Diabetes announces new data on Precision IGT and purchases key patent from True Health Liquidating Trust. Please see link below:

/PRNewswire/ -- Precision Diabetes, Inc. (PDI), an emerging leader in precision diabetes diagnostics, announced results today from a study on its Precision IGT...

10/07/2020

We just announced a global strategic alliance with Patia to commercialize precision diabetes diagnostics. Please see link.

/PRNewswire/ -- Patia Biopharma, SA, and Precision Diabetes, Inc. are pleased to announce they have entered into a global strategic alliance to transform the...

09/23/2020

We just announced a new study at the EASD 2020 meeting showing GlycoMark identifies high risk patients with diabetes. Please see link.

/PRNewswire/ -- According to new data presented at the 56th European Association for the Study of Diabetes (EASD) annual meeting, the GlycoMark blood test...

11/13/2019

November is ! Patient educational pamphlet now available in English, Spanish, and Chinese! Check out our latest .
https://glycomark.com/wp-content/uploads/2019/11/M-91-1A-Issue-21-GlycoMark-Newsletter-Approved.html

10/09/2019

Additional New GlycoMark® Test and SGLT-2 Inhibitor Clinical Data To Be Presented at the ADAAdvancing Precision Diabetes Medicine Symposium

New York, NY (October 7, 2019) — GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 201...

10/07/2019